Ken Griffin’s flagship hedge fund at Citadel climbs 15.1% in 2024

Ken Griffin’s flagship hedge fund at Citadel climbs 15.1% in 2024


Ken Griffin, Founder and C.E.O. of Citadel speaks during the New York Times annual DealBook summit at Jazz at Lincoln Center on December 04, 2024 in New York City.
Michael M. Santiago | Getty Images

Billionaire investor Ken Griffin’s handful of hedge funds at Citadel all posted double-digit returns in 2024, led by its tactical trading strategy.

Citadel’s multistrategy Wellington fund, its largest, finished the year up 15.1%, according to a person familiar with the returns. All five strategies used in the flagship fund — commodities, equities, fixed income, credit and quantitative — were positive for the year, the person said.

The Miami-based firm’s tactical trading fund was the standout performer with a 22.3% return for 2024, the person said. Citadel’s equity fund returned roughly 18%, while its global fixed income strategy gained 9.7% last year.

Citadel declined to comment. The hedge fund giant had $66 billion in assets under management as of December.

The stock market just closed out a banner year with the S&P 500 surging 23.3%, building on a gain of 24.2% in 2023. The two-year gain of 53% is the best since the nearly 66% rally in 1997 and 1998.

Griffin recently criticized the steep tariffs President-elect Donald Trump has vowed to implement, saying crony capitalism could be a consequence.

The CEO also said he’s not focused on taking Citadel Securities public in the foreseeable future. The securities firm is a Miami-based market maker founded by the 56-year-old Florida native in 2002.



Source

Stocks making the biggest moves midday: Nvidia, Ultragenyx Pharmaceutical, Newmont, DigitalBridge & more
Finance

Stocks making the biggest moves midday: Nvidia, Ultragenyx Pharmaceutical, Newmont, DigitalBridge & more

Check out some of the stocks making the biggest moves in midday trading. Ultragenyx Pharmaceutical – Shares cratered more than 40% after Ultragenyx announced that its bone disease drug setrusumab fell short of expectations in two trials. “Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo or bisphosphonates,” […]

Read More
Silver tops  for first time, then stages dramatic reversal overnight
Finance

Silver tops $80 for first time, then stages dramatic reversal overnight

Key Points Silver slid more than 3% on Monday, after topping $80 for the first time ever in overnight trading. The precious metal was still higher by more than 155% year to date. It started 2025 trading above just $20 per ounce. That has helped the precious metal outperform even gold this year. Source

Read More
Stocks making the biggest moves premarket: DigitalBridge, Praxis Precision Medicines, Coupang & more
Finance

Stocks making the biggest moves premarket: DigitalBridge, Praxis Precision Medicines, Coupang & more

Check out the companies making headlines before the bell: DigitalBridge — The private equity firm that invests in data centers and other assets surged more than 32% after Bloomberg News, citing unnamed sources, said Japan’s SoftBank is in advanced talks to acquire DigitalBridge. The deal could be announced as soon as Monday, Bloomberg reported. Nvidia […]

Read More